Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Equity Ratio: 2016-2025

Historic Equity Ratio for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to 0.29.

  • Rhythm Pharmaceuticals' Equity Ratio rose 851.80% to 0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29, marking a year-over-year increase of 851.80%. This contributed to the annual value of 0.06 for FY2024, which is 89.14% down from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Equity Ratio stood at 0.29 for Q3 2025, which was up 1,018.99% from -0.03 recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Equity Ratio peaked at 0.91 during Q3 2021, and registered a low of -0.03 during Q2 2025.
  • In the last 3 years, Rhythm Pharmaceuticals' Equity Ratio had a median value of 0.24 in 2024 and averaged 0.28.
  • Over the last 5 years, Rhythm Pharmaceuticals' Equity Ratio had its largest YoY gain of 851.80% in 2025, and its largest YoY loss of 131.01% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.86 in 2021, then decreased by 19.88% to 0.69 in 2022, then dropped by 26.16% to 0.51 in 2023, then crashed by 89.14% to 0.06 in 2024, then skyrocketed by 851.80% to 0.29 in 2025.
  • Its Equity Ratio stands at 0.29 for Q3 2025, versus -0.03 for Q2 2025 and 0.05 for Q1 2025.